One of the missions of NewG Lab Pharma (NGLP) will be to develop novel anticancer therapeutics that extend the life of cancer patients without compromising the quality of life.

NGLP will try to achieve its mission by recognizing the importance of whole-body metabolism of cancer patients rather than focusing only on the reduction of tumor burden. Based on the published statistics* there seems to be little correlation between overall survival benefits and tumor size.

Therefore, NGLP will keep in mind the aforesaid in its future development of anticancer therapeutics.

(Journal of Cancer : Prognostic Value of the Tumor Size in resectable Colorectal Cancer with Different Primary Locations: A Retrospective Study with the Propensity Score Matching, Jan. 1, 2019, Xiao Li, et al.
AJMS: Impact of tumor size on survival outcome of pancreatic carcinoma following pancreatic resection: A systematic review and meta-analysis, Jan. 1, 2018, Anuj Shrestha, et al.
PLOS : The prognostic role of tumor size in early breast cancer in the era of molecular biology, Dec. 6, 2017, Anaid Anna Kasangian, et al. )